Evoke Pharma (NASDAQ:EVOK) Now Covered by StockNews.com

Stock analysts at StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a report issued on Thursday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Down 3.6 %

Shares of NASDAQ EVOK opened at $4.30 on Thursday. Evoke Pharma has a 52 week low of $3.54 and a 52 week high of $12.32. The firm has a 50-day simple moving average of $4.49 and a 200-day simple moving average of $5.01. The stock has a market capitalization of $6.41 million, a price-to-earnings ratio of -0.39 and a beta of 0.15.

Evoke Pharma (NASDAQ:EVOK) last announced its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter. Evoke Pharma had a negative net margin of 71.32% and a negative return on equity of 308.49%. The firm had revenue of $2.65 million during the quarter.

Institutional Investors Weigh In On Evoke Pharma

A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. acquired a new stake in Evoke Pharma, Inc. (NASDAQ:EVOK) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned 1.42% of Evoke Pharma at the end of the most recent quarter.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.